间充质干细胞来源外泌体治疗慢性阻塞性肺疾病的机制及研究进展
艾钰 , 姜林鸿 , 李慧 , 刘博雅 , 张佳驰 , 李培君 , 刘晓丹
中国现代医学杂志 ›› 2026, Vol. 36 ›› Issue (17) : 43 -49.
间充质干细胞来源外泌体治疗慢性阻塞性肺疾病的机制及研究进展
Mechanisms and research progress of mesenchymal stem cell-derived exosomes in the treatment of chronic obstructive pulmonary disease
间充质干细胞来源外泌体(MSC-EXOs)是介导细胞间通信的关键介质,广泛参与炎症调控、免疫稳态、抗凋亡及组织修复等过程。近年研究表明,MSC-EXOs在慢性阻塞性肺疾病(COPD)的病理进程中扮演多重调节角色。其可通过调节免疫细胞极化、抑制炎症因子释放、促进肺泡上皮修复、抑制气道重塑及缓解氧化应激等机制,干预COPD的疾病进展。相较于传统干细胞疗法,MSC-EXOs具有低免疫原性、高生物相容性与良好的靶向修饰潜力,作为一种新兴的无细胞治疗策略,在COPD干预中展现出巨大潜力。该文首先概述MSC-EXOs的生物学特性,进而系统阐述其在COPD中的抗炎、组织修复、免疫调节及其他潜在作用,以期为COPD的治疗策略提供新的理论依据。
Mesenchymal stem cell-derived exosomes (MSC-EXOs) are important mediators of intercellular communication and are widely involved in physiological and pathological processes such as inflammation regulation, immune balance maintenance, inhibition of cell apoptosis and tissue repair. In recent years, basic research has demonstrated that MSC-EXOs exert multiple biological effects in the occurrence and development of chronic obstructive pulmonary disease (COPD). MSC-EXOs can intervene in the pathological process of COPD to a certain extent by regulating immune cell polarization, inhibiting the release of inflammatory factors, promoting alveolar epithelial repair, inhibiting airway remodeling and alleviating oxidative stress. Compared with traditional stem cell therapy, MSC-EXOs have the advantages of low immunogenicity, good biocompatibility and strong potential for targeted modification. As a new cell-free therapeutic strategy, MSC-EXOs show promising potential for COPD intervention. Based on the biological characteristics of MSC-EXOs, this review aims to systematically summarize their anti-inflammatory, tissue repair, immunomodulatory and other potential effects in COPD, and to provide a theoretical reference for their potential application in the treatment of COPD.
| [1] |
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021[J]. Lancet, 2024, 403(10440): 2133-2161. |
| [2] |
Yang I A, Jenkins C R, Salvi S S. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment[J]. Lancet Respir Med, 2022, 10(5): 497-511. |
| [3] |
Lai S M, Guo Z F. Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option[J]. Stem Cell Res Ther, 2024, 15(1): 312. |
| [4] |
Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, et al. Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools[J]. Stem Cell Res Ther, 2022, 13(1): 262. |
| [5] |
张议中, 马文文, 韩明轩, 外泌体用于卵巢癌诊断的研究进展[J]. 中国现代医学杂志, 2024, 34(23): 62-67. |
| [6] |
Li M Y, Li S S, Du C Y, et al. Exosomes from different cells: characteristics, modifications, and therapeutic applications[J]. Eur J Med Chem, 2020, 207: 112784. |
| [7] |
郭佳玲, 李晖, 曾子键, 间充质干细胞来源的外泌体治疗器官纤维化的研究进展[J]. 中国现代医学杂志, 2024, 34(9): 64-69. |
| [8] |
Jeppesen D K, Zhang Q, Franklin J L, et al. Extracellular vesicles and nanoparticles: emerging complexities[J]. Trends Cell Biol, 2023, 33(8): 667-681. |
| [9] |
刘宜隆, 吴迎. 细胞外囊泡在骨骼肌质膜损伤修复中的作用研究进展[J]. 生理学报, 2025, 77(5): 956-968. |
| [10] |
陈玉, 陈月桥, 黄钰雯, 外泌体调控自噬对肝脏相关疾病的作用及启示[J]. 中国现代医学杂志, 2025, 35(6): 45-50. |
| [11] |
Liu P P, Yang S N, Shao X C, et al. Mesenchymal stem cells-derived exosomes alleviate acute lung injury by inhibiting alveolar macrophage pyroptosis[J]. Stem Cells Transl Med, 2024, 13(4): 371-386. |
| [12] |
Tang J D, Wang X Y, Lin X, et al. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases[J]. Cell Death Discov, 2024, 10(1): 212. |
| [13] |
Zhou C C, Zhang B Y, Yang Y Q, et al. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing[J]. Stem Cell Res Ther, 2023, 14(1): 107. |
| [14] |
Wen Y M, Liang Z A. Enhanced itaconic acid secretion from macrophages mediates the protection of mesenchymal stem cell-derived exosomes on lipopolysaccharide-induced acute lung injury mice[J]. Biol Direct, 2024, 19(1): 138. |
| [15] |
Lin Z J, Wu Y L, Xu Y T, et al. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential[J]. Mol Cancer, 2022, 21(1): 179. |
| [16] |
Al-Khawaga S, Abdelalim E M. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients[J]. Stem Cell Res Ther, 2020, 11(1): 437. |
| [17] |
Rajabi H, Konyalilar N, Erkan S, et al. Emerging role of exosomes in the pathology of chronic obstructive pulmonary diseases; destructive and therapeutic properties[J]. Stem Cell Res Ther, 2022, 13(1): 144. |
| [18] |
Ridzuan N, Zakaria N, Widera D, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD)[J]. Stem Cell Res Ther, 2021, 12(1): 54. |
| [19] |
Han R F, Gao J, Wang L M, et al. MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye[J]. Sci Rep, 2023, 13(1): 11192. |
| [20] |
He C X, Li Z, Yang M, et al. Non-coding RNA in microglia activation and neuroinflammation in Alzheimer's disease[J]. J Inflamm Res, 2023, 16: 4165-4211. |
| [21] |
Yuan X Q, Li T F, Shi L, et al. Human umbilical cord mesenchymal stem cells deliver exogenous miR-26a-5p via exosomes to inhibit nucleus pulposus cell pyroptosis through METTL14/NLRP3[J]. Mol Med, 2021, 27(1): 91. |
| [22] |
Liang Z Y, Xu X J, Rao J, et al. Mesenchymal stem cell-derived exosomal MiRNAs promote M2 macrophages polarization: therapeutic opportunities for spinal cord injury[J]. Front Mol Neurosci, 2022, 15: 926928. |
| [23] |
Wang J M, Xia J, Huang R Q, et al. Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization[J]. Stem Cell Res Ther, 2020, 11(1): 424. |
| [24] |
Rodríguez-Pérez J, Andreu-Martínez R, Daza R, et al. Oxidative stress and inflammation in hypoxemic respiratory diseases and their comorbidities: molecular insights and diagnostic advances in chronic obstructive pulmonary disease and sleep apnea[J]. Antioxidants (Basel), 2025, 14(7): 839. |
| [25] |
Zhang W W, Wang T Y, Xue Y Y, et al. Research progress of extracellular vesicles and exosomes derived from mesenchymal stem cells in the treatment of oxidative stress-related diseases[J]. Front Immunol, 2023, 14: 1238789. |
| [26] |
Xiong Y L, Xiong Y L, Zhang H C, et al. hPMSCs-derived exosomal miRNA-21 protects against aging-related oxidative damage of CD4+ T cells by targeting the PTEN/PI3K-Nrf2 Axis[J]. Front Immunol, 2021, 12: 780897. |
| [27] |
Tang Y, Kang Y Y, Zhang X R, et al. Mesenchymal stem cell exosomes as nanotherapeutics for dry age-related macular degeneration[J]. J Control Release, 2023, 357: 356-370. |
| [28] |
Zhang Z H, Ge L L, Zhang S S, et al. The protective effects of MSC-EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway[J]. J Cell Mol Med, 2020, 24(23): 13938-13948. |
| [29] |
Ding C Y, Zhu L P, Shen H, et al. Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7[J]. Stem Cells, 2020, 38(9): 1137-1148. |
| [30] |
Raslan A A, Yoon J K. WNT signaling in lung repair and regeneration[J]. Mol Cells, 2020, 43(9): 774-783. |
| [31] |
Nan F Y, Liu B, Yao C. Discovering the role of microRNAs and exosomal microRNAs in chest and pulmonary diseases: a spotlight on chronic obstructive pulmonary disease[J]. Mol Genet Genomics, 2024, 299(1): 107. |
| [32] |
Zhu Y, Liao Z F, Mo M H, et al. Mesenchymal stromal cell-derived extracellular vesicles for vasculopathies and angiogenesis: therapeutic applications and optimization[J]. Biomolecules, 2023, 13(7): 1109. |
| [33] |
Gangadaran P, Rajendran R L, Lee H W, et al. Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia[J]. J Control Release, 2017, 264: 112-126. |
| [34] |
Maremanda K P, Sundar I K, Rahman I. Protective role of mesenchymal stem cells and mesenchymal stem cell-derived exosomes in cigarette smoke-induced mitochondrial dysfunction in mice[J]. Toxicol Appl Pharmacol, 2019, 385: 114788. |
| [35] |
Yi Y F, Fan Z Q, Liu C, et al. Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells[J]. World J Stem Cells, 2025, 17(3): 103560. |
| [36] |
Han X, Liao R D, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies[J]. Signal Transduct Target Ther, 2025, 10(1): 262. |
| [37] |
Lo Sicco C, Reverberi D, Balbi C, et al. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization[J]. Stem Cells Transl Med, 2017, 6(3): 1018-1028. |
| [38] |
Lourenço J D, Ito J T, Martins M D A, et al. Th17/Treg imbalance in chronic obstructive pulmonary disease: clinical and experimental evidence[J]. Front Immunol, 2021, 12: 804919. |
| [39] |
王傲晨, 陈旭. 间充质干细胞外泌体通过免疫调节促进组织再生的研究进展[J]. 中国医科大学学报, 2020, 49(10): 954-957. |
| [40] |
Suo R, Hao T X, Wumaier R X G L, et al. Mesenchymal stem cell-derived exosomes: a new hope for improving asthma airway remodeling[J]. Ann Med, 2025, 57(1): 2591447. |
| [41] |
Harrell C R, Miloradovic D, Sadikot R, et al. Molecular and cellular mechanisms responsible for beneficial effects of mesenchymal stem cell-derived product "Exo-d-MAPPS" in attenuation of chronic airway inflammation[J]. Anal Cell Pathol (Amst), 2020, 2020: 3153891. |
| [42] |
Wan X, Chen S Y, Fang Y, et al. Mesenchymal stem cell-derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA-29b-3p in idiopathic pulmonary fibrosis[J]. J Cell Physiol, 2020, 235(11): 8613-8625. |
| [43] |
Xie H, Gao Y M, Zhang Y C, et al. Low let-7d exosomes from pulmonary vascular endothelial cells drive lung pericyte fibrosis through the TGFβRI/FoxM1/smad/β-catenin pathway[J]. J Cell Mol Med, 2020, 24(23): 13913-13926. |
| [44] |
Mansouri N, Willis G R, Fernandez-Gonzalez A, et al. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes[J]. JCI insight, 2019, 4(21): 128060. |
| [45] |
Kou M, Huang L, Yang J J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?[J]. Cell Death Dis, 2022, 13(7): 580. |
| [46] |
Wu D, Kang L, Tian J J, et al. Exosomes derived from bone mesenchymal stem cells with the stimulation of Fe3O4 nanoparticles and static magnetic field enhance wound healing through upregulated miR-21-5p[J]. Int J Nanomedicine, 2020, 15: 7979-7993. |
| [47] |
Panda B, Sharma Y, Gupta S, et al. Mesenchymal stem cell-derived exosomes as an emerging paradigm for regenerative therapy and nano-medicine: a comprehensive review[J]. Life (Basel), 2021, 11(8): 784. |
| [48] |
Jahangiri B, Khalaj-Kondori M, Asadollahi E, et al. MSC-derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway[J]. Int J Pharm, 2022, 627: 122214. |
国家自然科学基金(82372573)
国家自然科学基金(82072551)
上海市卫生健康委员会卫生健康学科带头人项目(2022XD044)
上海市“超级博士后”资助项目(2022510)
/
| 〈 |
|
〉 |